ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Commercial launch of TLANDO™ (oral testosterone undecanoate)
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 225710" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.prnewswire.com/news-releases/halozyme-announces-commercial-launch-of-tlando-an-oral-treatment-for-testosterone-replacement-therapy-301562608.html[/URL]</p><p></p><p><strong>SAN DIEGO, June 7, 2022 /PRNewswire/ -- </strong><em><strong>Halozyme Therapeutics, Inc. (NASDAQ: <a href="https://www.prnewswire.com/news-releases/halozyme-announces-commercial-launch-of-tlando-an-oral-treatment-for-testosterone-replacement-therapy-301562608.html#financial-modal" target="_blank">HALO</a>) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism).</strong> <strong>TLANDO™ was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>"We are delighted to announce the commercial availability of TLANDO and provide patients with a convenient oral dosing option for testosterone replacement therapy.</strong> The launch of TLANDO represents our second testosterone replacement therapy product, following the 2018 launch of XYOSTED, a weekly subcutaneous auto-injector. The TLANDO approval and commercial launch demonstrate our continued commitment to developing new drug delivery options for patients," commented Dr. Helen Torley, president, and chief executive officer of Halozyme. "We look forward to expanding our market share in this growing therapeutic category with both XYOSTED and TLANDO." </em></p><p><em></em></p><p><em>"Our sales organization is well-positioned to leverage its experience and physician relationships established through the commercialization of XYOSTED," said Joe Renda, senior vice president, commercial of Halozyme. <strong>"We believe TLANDO's oral formulation and convenient dosing, which requires no titration, are key benefits for physicians and patients." </strong></em></p><p></p><p>For full prescribing information, please visit <a href="https://c212.net/c/link/?t=0&l=en&o=3559395-1&h=44187692&u=http%3A%2F%2Fwww.tlando.com%2F&a=www.TLANDO.com" target="_blank">www.TLANDO.com</a>.</p><p></p><p><strong>About Hypogonadism</strong></p><p>Male hypogonadism is an endocrine disorder in which the body fails to produce enough testosterone. Hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes. It is estimated that approximately 35% of men older than 45 years of age and 30-50% of men with obesity or type 2 diabetes have hypogonadism1. Hypogonadism can be treated with testosterone replacement therapy.</p><p></p><p><strong>1</strong> Endocrine Society</p></blockquote><p></p>
[QUOTE="madman, post: 225710, member: 13851"] [URL unfurl="true"]https://www.prnewswire.com/news-releases/halozyme-announces-commercial-launch-of-tlando-an-oral-treatment-for-testosterone-replacement-therapy-301562608.html[/URL] [B]SAN DIEGO, June 7, 2022 /PRNewswire/ -- [/B][I][B]Halozyme Therapeutics, Inc. (NASDAQ: [URL='https://www.prnewswire.com/news-releases/halozyme-announces-commercial-launch-of-tlando-an-oral-treatment-for-testosterone-replacement-therapy-301562608.html#financial-modal']HALO[/URL]) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism).[/B] [B]TLANDO™ was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022. "We are delighted to announce the commercial availability of TLANDO and provide patients with a convenient oral dosing option for testosterone replacement therapy.[/B] The launch of TLANDO represents our second testosterone replacement therapy product, following the 2018 launch of XYOSTED, a weekly subcutaneous auto-injector. The TLANDO approval and commercial launch demonstrate our continued commitment to developing new drug delivery options for patients," commented Dr. Helen Torley, president, and chief executive officer of Halozyme. "We look forward to expanding our market share in this growing therapeutic category with both XYOSTED and TLANDO." "Our sales organization is well-positioned to leverage its experience and physician relationships established through the commercialization of XYOSTED," said Joe Renda, senior vice president, commercial of Halozyme. [B]"We believe TLANDO's oral formulation and convenient dosing, which requires no titration, are key benefits for physicians and patients." [/B][/I] For full prescribing information, please visit [URL='https://c212.net/c/link/?t=0&l=en&o=3559395-1&h=44187692&u=http%3A%2F%2Fwww.tlando.com%2F&a=www.TLANDO.com']www.TLANDO.com[/URL]. [B]About Hypogonadism[/B] Male hypogonadism is an endocrine disorder in which the body fails to produce enough testosterone. Hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes. It is estimated that approximately 35% of men older than 45 years of age and 30-50% of men with obesity or type 2 diabetes have hypogonadism1. Hypogonadism can be treated with testosterone replacement therapy. [B]1[/B] Endocrine Society [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Commercial launch of TLANDO™ (oral testosterone undecanoate)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top